logo
logo

Karolinska Development’s Portfolio Company Aprea Therapeutics Secures Funding Of Usd 5.5 Million

Feb 28, 2023•over 2 years ago
StockholmHealth CareScience And EngineeringBiotechnology

Description

STOCKHOLM, SWEDEN, February 28, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has closed an underwritten public offering of USD 5.5 million before deducting underwriting discounts, commissions, and offering expenses.

Company Information

Company

Aprea Therapeutics

Location

Stockholm, Stockholm County, Sweden

About

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Doylestown, Pennsylvania, focused on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. The Company’s lead program is ATRN-119, a Phase 1-ready small molecule ATR inhibitor being developed for solid tumor indications. For more information, please visit the company website at www.aprea.com. The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

FundzWatch™ Score

61
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People